Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Duocarmycins--natures prodrugs?

¹Department of Pharmaceutical and Biological Chemistry, University of London School of Pharmacy, 29/39 Brunswick Square, London, WC1N 1AX, UK. mark.searcey@ams1.ulsop.ac.uk

Current Pharmaceutical Design

|June 8, 2002

Summary

Duocarmycins and (+)-CC-1065 are potent anticancer drugs activated by DNA binding. Targeting these natural products to tumors is crucial for clinical advancement, as they act as prodrugs upon target engagement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in triterpene drug discovery.

Trends in pharmacological sciences·2024

Same author

IS4-FAM, a fluorescent tool to study CXCR4 affinity and competitive antagonism in native cancer cells.

Pharmacology research & perspectives·2024

Same author

Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction.

Chemical communications (Cambridge, England)·2024

Same author

Borylation <i>via</i> iridium catalysed C-H activation: a new concise route to duocarmycin derivatives.

Organic & biomolecular chemistry·2024

Same author

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug.

Experimental parasitology·2024

Same author

The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis.

Biochemical pharmacology·2023

Area of Science:

Natural Products Chemistry
Medicinal Chemistry
Oncology

Background:

Duocarmycins and (+)-CC-1065 are highly potent antitumour antibiotics.
Despite their efficacy, they have not advanced into clinical use.
These compounds exhibit remarkable stability against nucleophilic attack until DNA binding.

Purpose of the Study:

To discuss the mechanism of target activation for duocarmycins.
To explore strategies for targeting these agents to tumor sites.
To review existing methods and future directions for prodrug development.

Main Methods:

Analysis of duocarmycin activation mechanisms (acid-catalyzed and binding-induced).
Review of targeting strategies for CC-1065 and duocarmycins.
Evaluation of systemic prodrug activation approaches.

Main Results:

Duocarmycins are activated via acid catalysis or conformational changes upon DNA binding.
The natural product itself functions as a prodrug, activated by target binding.
Targeting to tumor sites is suggested as more critical than systemic prodrug activation.

Conclusions:

The inherent prodrug nature of duocarmycins emphasizes the importance of targeted delivery.
Further research into structural modifications for improved targeting is warranted.
Overcoming clinical limitations may involve optimizing delivery rather than systemic activation.

Related Experiment Videos